← All trials
NCT05311085
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 6, 2022
- Primary completion
- Feb 29, 2024
- Completion date
- Feb 29, 2024
- First posted
- Apr 5, 2022
- Last posted
- May 18, 2022
- Enrollment
- 800
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AucklandLead sponsor
- University of AucklandOverall official - principal investigator
- University of AucklandReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.